Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples